Lung Cancer

A neurologist explains how to test for and diagnose Lambert-Eaton myasthenic syndrome.

David Gerber, MD, and Steven Vernino, MD, PhD, provide an overview of Lambert-Eaton myasthenic syndrome and its association with cancers.

The FDA approvals of several targeted therapies, such as sotorasib, amivantamab-vmjw, and mobocertinib, as well as immunotherapeutic strategies, such as adjuvant atezolizumab, represent significant advances made in 2021 for the treatment of patients with non–small cell lung cancer.

Drs Peters and Mok discuss adjuvant therapy for patients with early-stage EGFR mutant NSCLC and the impact of the ADAURA clinical trial on how we treat this disease.

Solange Peters, MD, PhD, and Tony SK Mok, MD, delve into the importance of molecular testing for EGFR mutant non-small cell lung cancer, including guidelines and commonly found barriers.

Stephen Liu, MD, reviews outcomes from the IMpower133 trial and comments on the current standard of care for the first-line treatment of extensive-stage SCLC.

John V. Heymach, MD, PhD, provides an overview of small cell lung cancer (SCLC), and Ani Balmanoukian, MD, reviews available treatment options for limited-stage disease.

Christine Bestvina, MD, discusses the emerging role of neoadjuvant chemoimmunotherapy in lung cancer.

Preliminary research with datopotamab deruxtecan has shown a promising, unprecedented duration of response in heavily pretreated patients with non–small cell lung cancer.

Charu Aggarwal, MD, MPH, discusses the significance of the phase 3 IMpower010 trial in patients with PD-L1–positive non–small cell lung cancer.

Lung cancer experts provide insight on updates from key clinical trials presented at ESMO 2021 on PD-1 inhibitor–resistant NSCLC.

Dr Heather Wakelee reviews results from the IMpower110 study for first-line metastatic NSCLC treatment.

Konstantinos Arnaoutakis, MD, discusses the phase 3 ADAURA trial examining osimertinib in the adjuvant treatment of patients with EGFR-mutant lung cancer.

In this clinical case review, a panel of community experts discusses the management of immunotherapy in patients with NSCLC, reflects on factors affecting treatment selection and sequencing, and examines the evolving landscape of immunotherapy-based treatment approaches.

Christine Bestvina, MD, discusses challenges with interpreting molecular reports in lung cancer.

A new drug application seeking the approval of poziotinib as a potential therapeutic option for patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations has been submitted to the FDA.

Heather Wakelee, MD, shares updates from the CheckMate 9LA study, and Vamsidhar Velcheti, MD, reviews key data from the phase 3 POSEIDON study for patients with NSCLC.

Experts in lung cancer discuss recent updates from ESMO 2021 and IASLC 2021 WCLC on combination immunotherapy plus chemotherapy for the treatment of advanced NSCLC.

Ticiana Leal, MD, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer.

Nasser Khaled Altorki, MD, provides insight on the results of the IMpower010 trial as well as post hoc analyses from the trial and what they signal for the remainder of this patient population.

Edward B. Garon, MD, discusses the potential impact of the ongoing, phase 3 TROPION-LUNG01 trial in non–small cell lung cancer.

The FDA has issued a complete response letter to the new drug application seeking the approval of plinabulin in combination with granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

In this clinical case review, academic experts share insights into the disease management of patients with NSCLC, discuss factors impacting treatment selection and sequencing strategies, and evaluate the evolving landscape of immunotherapy-based regimens.

Rodolfo Bordoni, MD, discusses the utility of ​atezolizumab in the adjuvant setting in non–small cell lung cancer.

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.